{
    "clinical_study": {
        "@rank": "1588", 
        "arm_group": {
            "arm_group_label": "Lesinurad and  [14C]lesinurad", 
            "arm_group_type": "Experimental", 
            "description": "Single oral dose of lesinurad and single infusion of [14C]lesinurad"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the absolute bioavailability of a single oral dose of lesinurad and\n      evaluate the pharmacokinetic (PK) parameters of lesinurad and [14C]lesinurad in healthy\n      adult male subjects."
        }, 
        "brief_title": "Bioavailability of Lesinurad and Intravenous [14C]Lesinurad", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "In this study a single dose of lesinurad will be administered after an overnight fast\n      followed by a single 15-minute infusion of a radiolabeled intravenous micro tracer dose of\n      [14C]lesinurad to assess the in vivo performance of lesinurad."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs) and body mass index \u2265 18 and \u2264 30 kg/m2.\n\n          -  Subject is free of any clinically significant disease or medical condition, per the\n             Investigator's judgment\n\n        Exclusion Criteria:\n\n          -  Subject has a history or suspicion of kidney stones.\n\n          -  Subject has undergone major surgery within 3 months prior to Screening.\n\n          -  Subject donated blood or experienced significant blood loss (>450 mL) within 12 weeks\n             prior to Screening or gave a plasma donation within 4 weeks prior to Screening.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture.\n\n          -  Subject does not have a normal or clinically acceptable physical examination, per the\n             Investigator's judgment.\n\n          -  Subject has clinically relevant abnormalities in blood pressure, heart rate, or body\n             temperature, per the Investigator's judgment.\n\n          -  Subject has Screening clinical safety laboratory parameters (serum chemistry,\n             hematology, or urinalysis) that are outside the normal limits and are considered\n             clinically significant by the Investigator.\n\n          -  Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the\n             Investigator's judgment.\n\n          -  Subject has a Screening serum urate level > 7 mg/dL.\n\n          -  Subject had radiation exposure that exceeds 5 mSv in the last 12 months or 10 mSv in\n             the last 5 years.  This includes radiation exposure from the present study or other\n             clinical studies, including diagnostic X-rays and other medical exposures but\n             excluding exposure to background radiation.  No occupationally exposed worker, as\n             defined in the Ionising Radiation Regulations 1999, shall participate in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039700", 
            "org_study_id": "RDEA594-131"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lesinurad and  [14C]lesinurad", 
                "intervention_name": "Lesinurad 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad and  [14C]lesinurad", 
                "intervention_name": "[14C]lesinurad (100 \u03bcg per 10 mL)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Study to Assess the Absolute Bioavailability of a Single Oral Dose of Lesinurad With Respect to an Intravenous Micro Tracer Dose of [14C]Lesinurad in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "J. Hall", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "PK profile in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), apparent terminal half-life (t\u00bd), mean residence time (MRT), mean absorption time (MAT), and absolute bioavailability (F).", 
                "measure": "Characteristics of bioavailability in terms of lesinurad Pharmacokinetics (PK) profile from plasma.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 5"
            }, 
            {
                "description": "PK profile in terms of Cmax, AUC, t\u00bd, MRT, total body clearance (CL), and volume of distribution at steady state (Vss).", 
                "measure": "PK profile of [14C]lesinurad from plasma", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 5"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039700"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}